Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2015
Event: Entry into a Material Definitive Agreement for a private placement offering.
Key Financial Metrics
This filing details a capital raise rather than operational performance metrics. Specific figures include:
- Securities Issued: 1,834,299 units (each consisting of one share of common stock and a five-year warrant to purchase 0.5 shares).
- Purchase Price: $0.67 per unit.
- Warrant Exercise Price: $0.85 per warrant share.
- Gross Proceeds: Approximately $1.23 million (before expenses).
- Insider Participation: Directors Matthew Rosenberg and the spouse of Malcolm Persen committed to purchasing units for an aggregate of $154,877 ($134,000 and $20,877 respectively).
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement on May 12, 2015, authorizing the sale of equity securities to accredited investors. The closing of the transaction is scheduled to occur no later than May 19, 2015.
Outlook, Risks, and Contingencies
- Registration Obligation: The Company agreed to file a registration statement with the SEC to register the resale of the Shares and Warrant Shares.
- Liquidated Damages: If the registration statement is not filed within 60 days following the closing, the Company must pay investors 1% of their aggregate investment amount per month until filing occurs.
- Regulatory Exemption: The offering relies on exemptions under Section 4(2) of the Securities Act and/or Rule 506, as it involves only accredited investors and no general solicitation.
Investor Verification Checklist
- Confirm the actual closing date of the offering (expected by May 19, 2015).
- Verify the filing of the registration statement for resale of securities within the 60-day post-closing window to avoid liquidated damages.
- Review the final number of shares issued and total net proceeds after deducting transaction expenses.
- Assess the dilution impact of the 1,834,299 new shares and the potential issuance of up to 917,150 additional shares via warrant exercise.